Scientific Vision

At Imago, our research is focused on therapeutics that alter gene expression patterns by targeting enzymes that regulate gene transcription – the factors that control how genes are turned on and off in specific cells.

Significant progress has been made over the past ten years in understanding epigenetic regulation of gene expression. Researchers and drug developers are now exploring the therapeutic potential of modifying DNA without changing the sequence in order to turn genes on and off.

Imago was founded to understand more deeply this scientific signaling process, and to exploit regulators to alter gene expression for therapeutic benefit. Our therapies have their most profound effects on abnormal cells, and may be combined with existing treatments to either restore healthy cellular function or to purge those cells that cannot be rendered harmless.

Scientific Vision
The three systems that can silence genes by interacting with each other include DNA methylation, chromatin modifications and RNA silencing. One clinical epigenetic approach has been to inhibit both DNA methylation and histone deacetylation with a variety of agents. This approach has had some impact on MDS and AML but these diseases involve other modifications of chromatin. Epigenetic mechanisms directly implicated in MDS and AML are the focus of our research and development program